Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Authors' conclusion
We observed weight loss of 9.1% and 21.4% and improved glucose control in semaglutide and tirzepatide users, respectively, after 1 year of off-label use.
Study context
- Population
- Overweight or obese adults with T1D followed in a specialty diabetes clinicmatched controls
- Participants
- 50 / 50 / 50
- Exposure
- Semaglutide or tirzepatide vs no weight loss medication
- Semaglutiden = 50
- Tirzepatiden = 50
- Controlsn = 50reference
- Outcome
- Weight change
- Follow-up
- 12 months
Methodological detailscontrols frequency matched for age, sex, diabetes duration, BMI and HbA1c, single specialty diabetes clinic
- Controls frequency matched for age, sex, diabetes duration, BMI and HbA1c
- Single specialty diabetes clinic
Main finding
As reported in the abstract
| Outcome | Semaglutide | Tirzepatide |
|---|---|---|
| Weight change · 12 months | −19.2 (SE 2.9) lbs. | −49.4 (SE 3.0) lbs. |
| Body weight lost | 9.1% | 21.4% |
Observational data: associations, not effects.
Further findings
| Outcome | Semaglutide | Tirzepatide |
|---|---|---|
| HbA1c change · 12 months | −0.54 (SE 0.14) % | −0.68 (SE 0.16) % |
| P | P = 0.0001 | P < 0.0001 |
HbA1c change · 12 months
- HbA1c didn't change in controls
Original publication
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →